Custom-Made vaccine fights kidney cancer in early trial
NCT ID NCT00458536
First seen Feb 10, 2026 · Last updated Apr 24, 2026 · Updated 12 times
Summary
This early-phase trial tested a personalized vaccine for people with advanced kidney cancer. The vaccine was made by fusing a patient's own immune cells with their tumor cells, aiming to train the body to attack the cancer. The main goals were to check safety and see if the vaccine could trigger an immune response. 38 participants were enrolled, and the study is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.